Literature DB >> 32591922

Harnessing Newton's third-law paradigm to treat autoimmune diseases and chronic inflammations.

Tue Gia Nguyen1.   

Abstract

PURPOSE: It paradoxically seems counter-intuitive to consider treatments that activate the immune systems as a method to treat autoimmune diseases and chronic inflammations when these inflammatory conditions are themselves manifested by dysregulated activations of the immune responses. However, according to Newton's Third-Law of fundamental physics which formally states "For every action, there is an equal and opposite reaction", it can be reasonably argued that "For every activated pro-inflammatory response, there is an opposite and intrinsic anti-inflammatory response to follow." Therefore, harnessing these intrinsic self-regulated negative-feedbacks of anti-inflammatory and tolerogenic responses by activating the immune systems represents a novel therapeutic paradigm.
METHODS: This review endeavoured to examine and discuss the current clinical and experimental evidences and therapeutic potentials of activating the innate and adaptive immune systems via their classical cell receptors, namely Toll-like receptors (TLRs), T-cell receptors (TCRs), and B cell receptors (BCRs), to modulate and suppress pathogenic inflammations.
RESULTS: The evidence presented in this review illustrated the therapeutic potentials and the caveats of  recent approaches and advances in harnessing this unorthodox therapeutic paradigm in the treatments of autoimmune diseases, allergic and chronic inflammations. It highlighted the promising potentials of targeting BCR-activated tolergenic responses as a new approach in this new therapeutic paradigm.

Entities:  

Keywords:  Adaptive immunity; Allergy; Autoimmune diseases; B cells; IgD; Immune tolerance; Immunomodulation; Immunotherapy; Inflammation; Innate immunity

Mesh:

Substances:

Year:  2020        PMID: 32591922     DOI: 10.1007/s00011-020-01374-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   6.986


  89 in total

1.  Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology.

Authors:  Sarah C Higgins; Ed C Lavelle; Chantelle McCann; Brian Keogh; Edel McNeela; Patricia Byrne; Brian O'Gorman; Andrew Jarnicki; Peter McGuirk; Kingston H G Mills
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

2.  Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.

Authors:  L Chatenoud; C Legendre; C Ferran; J F Bach; H Kreis
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

3.  Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases.

Authors:  A D Foey; S L Parry; L M Williams; M Feldmann; B M Foxwell; F M Brennan
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

Review 4.  Control of adaptive immunity by the innate immune system.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2015-04       Impact factor: 25.606

Review 5.  T Cell Co-stimulation and Functional Modulation by Innate Signals.

Authors:  Takayuki Imanishi; Takashi Saito
Journal:  Trends Immunol       Date:  2020-02-05       Impact factor: 16.687

Review 6.  Cytokines as a link between innate and adaptive antitumor immunity.

Authors:  Filippo Belardelli; Maria Ferrantini
Journal:  Trends Immunol       Date:  2002-04       Impact factor: 16.687

7.  Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis.

Authors:  Monica Marta; Asa Andersson; Magnus Isaksson; Olle Kämpe; Anna Lobell
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

8.  LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism.

Authors:  Tone Bryn; Sheraz Yaqub; Milada Mahic; Karen Henjum; Einar M Aandahl; Kjetil Taskén
Journal:  Int Immunol       Date:  2007-12-20       Impact factor: 4.823

9.  IL-7 treatment augments and prolongs sepsis-induced expansion of IL-10-producing B lymphocytes and myeloid-derived suppressor cells.

Authors:  Upasana Kulkarni; Christoph Herrmenau; Stephanie J Win; Michael Bauer; Thomas Kamradt
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

10.  Do adaptive immune cells suppress or activate innate immunity?

Authors:  Jie Zhao; Xuanming Yang; Sogyong L Auh; Kwang Dong Kim; Hong Tang; Yang-Xin Fu
Journal:  Trends Immunol       Date:  2008-12-06       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.